We are in the age of Artificial intelligence. Every day we do entertainment experiments with images related to anime or answers to curious facts from the anime. ChatGPTwhile experts use the machine learning mechanisms to manufacture products capable of curing diseaseslike this medicine that generates controversy throughout the world.
A drug created entirely by Artificial Intelligence has passed the second phase of clinical trials and is about to start being tested in humans. Obviously, it is accompanied by scientists who observe in detail the benefits and contraindications of the drug.
According to a review by infobaethe drug is called INS018_055. It is intended to treat idiopathic pulmonary fibrosis (IPF), a chronic disease that affects the lungs. The company that makes it is called Insilico Medicine and is based in Hong Kong.
Its manufacturing process was done through algorithms generated by Artificial Intelligence. Alex Zhavoronkov, founder and CEO of Insilico Medicine, said that they decided to address this lung condition due to the scarcity of effective treatments, which only sought to delay its progression and not eliminate the disease permanently.
“We hope to get the results of the phase II trial next year. We are optimistic that this drug will be ready for the market and will reach patients who can benefit from it in the coming years”, said Alex Zhavoronkov.
It is not the only disease that this company wants to treat with drugs generated by Artificial Intelligence. They have one against cancer; a “USP1 inhibitor for the treatment of solid tumors”, which recently received approval from the United States Food and Drug Administration (FDA) for the first process of clinical trials.